Clinical Roundup Dual-targeted therapies + chemo shows high response rates in BRAF-mutated metastatic CRC, phase III trial shows January 31, 2025Vol.51 No.04
Clinical Roundup Opdivo + Yervoy show improvement in PFS for MSI-high, MMR- CRC in phase III trial January 31, 2025Vol.51 No.04
Clinical Roundup Genentech’s Itovebi demonstrated OS benefit in advanced breast cancer, phase III trial finds January 31, 2025Vol.51 No.04
Clinical Roundup In HER2+ CRC, anti-HER2 therapy may be less toxic alternative to EGFR inhibitors, phase II study finds January 31, 2025Vol.51 No.04
Clinical Roundup Chemo + immunotherapy achieve higher complete remission rates in DLBCL than either treatment alone, Mount Sinai trial finds January 31, 2025Vol.51 No.04
Clinical Roundup Adjuvant Celebrex may reduce risk of colon cancer recurrence in patients with evidence of ctDNA January 31, 2025Vol.51 No.04
Clinical Roundup SWOG study: Statistical tool provides more accurate estimates of recurrence risk and chemotherapy benefit in breast cancer January 24, 2025Vol.51 No.03
Clinical Roundup DFCI researchers use PET imaging to detect body inflammation January 24, 2025Vol.51 No.03
Clinical Roundup Deadly dog cancer reveals clues for improved treatment, UF study finds January 24, 2025Vol.51 No.03
Clinical Roundup NCCN guidelines updated to include ctDNA-MRD testing recommendation for B-cell lymphoma January 17, 2025Vol.51 No.02
